InMed Set for Breakout Amid Promising Alzheimer's Trial

InMed (INM) — Final Days of the Prediction Window
INM is a microcap biotech (~$5M) developing cannabinoid-based therapies with INM-901 targeting Alzheimer’s and INM-089 for macular degeneration. The July prediction flagged a potential run from $2.90 toward $5.50 by September, tied to Alzheimer’s trial catalysts. Since then, InMed raised $5M through private placements, improved its EPS YoY, and presented encouraging INM-901 data at AAIC 2025.

With the window (Aug–Sept) now closing, all eyes are on whether additional trial updates or regulatory milestones emerge. This remains a high-risk, high-reward speculative play: dilution is a risk, but any positive Alzheimer’s data could send INM soaring well beyond its current ~$5M valuation. Worth watching closely as Q4 begins.

Consider also that Orbo has, on at least one documented occasion, predicted the close a bit early, and the stock made a late breakout, as with FGEN … however; holding past the window would also present other risks.

Advice as the Window Nears Close

• Catalyst Timing: The prediction window (Aug 1 – Sep 30) is basically ending now. Unless they announce a clinical trial update for INM-901 in the next few days, the move may stall or roll into the next quarter.
• Financial Picture: They’ve already leaned on private placements twice in June to raise $5M. With EPS still negative (though improving YoY), expect dilution risk to remain a theme. This makes timing around news crucial.
• Alzheimer’s Angle: If INM-901 keeps producing positive data, it gives them a much bigger story than their $5M market cap reflects. Even whispers of FDA engagement could ignite the stock.
• Trading Perspective: With such a tiny float and sub-$10M cap, price action can swing violently. If you’re already in, the risk is dilution or a quiet period; the upside is an explosive run on any data readout or partnership news.
• Tactical Move: If no news drops by Sept 30, consider whether to keep a trailing stop or scalp partial profits if you caught the run up from the $2.90 prediction level. A hold into Q4 is speculative but could still pay if they time another catalyst (conference, FDA meeting, or updated Alzheimer’s results).